Asymchem Laboratories (Tianjin) Co., Ltd.
6821.HKHKSEHealthcareBiotechnology
Latest quote
HK$112.1
−HK$7.70 · -6.43%
6821.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteAsymchem Laboratories (Tianjin) Co., Ltd. functions as a Contract Development and Manufacturing Organization (CDMO), offering its services to clients across Mainland China and internationally. The company delivers extensive drug research, development, and manufacturing solutions specifically tailored for pharmaceutical and biotechnology enterprises. Their offerings are comprehensive, covering the entire lifecycle from early clinical stages through to full commercialization, including R&D and cGMP compliant production of advanced intermediates, active pharmaceutical ingredients (APIs), and finished formulations, alongside clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the sale and distribution of medicinal products, and active participation in pharmaceutical science and technology innovation. The company was founded in 1999 and maintains its headquarters in Tianjin, China.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Hao Hong
- Listed since
- Dec 10, 2021
- Employees
- 10,617
Market position
Day range
Current HK$112.1
52-week range
Current HK$112.1
- Open
- HK$119.9
- Previous close
- HK$119.8
- Volume
- 863.6K
- 1.02× average
- Average volume
- 845.16K
- Average daily volume
- Market cap
- 40.44B HKD
- Beta
- 0.06
- Market reference 1
- 50-day average
- HK$113.97
- -1.64% below average
- 200-day average
- HK$92.8548
- +20.73% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 16.63B CNY
- P/E (TTM)
- 50.86×
- P/B (TTM)
- 3.19×
- P/S (TTM)
- 7.6×
- EV / EBITDA
- 8.99×
- Earnings yield
- 4.99%
- Free cash flow yield
- 0.60%
- Dividend yield
- 0.82%
Profitability & efficiency
- Gross margin
- 41.95%
- Operating margin
- 24.45%
- Net margin
- 16.02%
- Return on equity
- 6.42%
- Return on assets
- 5.59%
- Return on invested capital
- 5.91%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 5.85×
- Altman Z-score
- 9.74
- Piotroski F-score
- 7 of 9
Earnings
- EPS beat rate
- 33%
- 2 beats, 4 misses, 0 met estimates
- Average EPS surprise
- -15.45%
- 6 comparable reports
- Latest EPS result
- 0.96
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
6821.HK peers
ETFs holding 6821.HK
Funds reporting this stock among their holdings, ordered by reported position size.
Goldman Sachs MarketBeta Emerging Markets Equity ETFGSEE- Market value
- 11.28K
- Weight
- 0.01%
- AUM
- 137.09M USD
- Expense ratio
- 0.45%
- Price / 1D
- $69.03+0.94%
Goldman Sachs MarketBeta Total International Equity ETFGXUS- Market value
- 7.23K
- Weight
- —
- AUM
- 644.55M USD
- Expense ratio
- 0.18%
- Price / 1D
- $64.80+0.81%
Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETFEMCR- Market value
- 6.51K
- Weight
- 0.01%
- AUM
- 61.55M USD
- Expense ratio
- 0.15%
- Price / 1D
- $43.60+0.58%
Continue in GoAI
Research 6821.HKresearch.disclaimer